1GLOBAL
22.1.2024 18:18:25 CET | Business Wire | Press release
Kuwait-based low-cost airline Jazeera Airways has partnered with London headquartered Telco 1GLOBAL to become the first airline in the MENA region to launch its own travel eSIM offering. The collaboration will enable Jazeera passengers to communicate cost-effectively and avoid expensive roaming costs when travelling. At the same time, it will serve to strengthen Jazeera Airways´ customer loyalty and satisfaction, while boosting ancillary revenues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240122511628/en/
Yousef Al Qatami, Chief of Staff at 1GLOBAL. (Source: 1GLOBAL)
Leveraging the power of eSIM
Through the partnership 1GLOBAL will integrate its consumer eSIM technology into Jazeera Airlines' service offering. The process will begin with the implementation of a Jazeera branded QR code and web-based solution, followed by a full-fledged integration into the Jazeera Airways app. The white label solution allows Jazeera to offer eSIM services while maintaining the airlines own look and feel.
Andrew Ward, Vice President Marketing & Customer Experience at Jazeera Airways, says: "We are delighted to be able to offer the 1GLOBAL service to our passengers. We are always looking for ways to reduce travel costs and the 1GLOBAL eSIM offers low call rates for travellers across the Jazeera network."
A benefit for both the airline and its passengers
The roaming solution will be marketed through various communication channels including social media, in-flight magazines, email confirmations and promotional material in airport terminals. The partnership offers benefits for both travellers and Jazeera Airways. By activating the 1GLOBAL roaming eSIM, travellers will be able to stay connected more cost effectively than if they were using their standard roaming plan. They will also have access to high quality 5G & 4G coverage in almost all countries with plenty of flexible tariff options to choose from. Jazeera Airways on the other hand hopes to increase customer loyalty by providing this value-added service. This initiative not only distinguishes Jazeera Airways from its competitors through innovative offerings, but it also aims to increase revenue through ancillary services.
Yousef Al Qatami, Chief of Staff at 1GLOBAL, emphasises: "We are very proud to have supported the Jazeera Airways team in being the first airline in the MENA region to launch an eSIM offering. We are confident in the region's growth trajectory and hope to bring the benefits of eSIM to more local businesses and customers."
About Jazeera Airways
Jazeera Airways operates commercial and cargo flights out of its Jazeera Terminal T5 at Kuwait International Airport. The airline flies to over 64 popular destinations across the Middle East, Central and South Asia, Africa and Europe comprising high-demand business, leisure, religious and weekend destinations.
About 1GLOBAL
Founded in 2022, 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognized GSMA-accredited global mobile network. Headquartered in London with our R&D hub in Lisbon, we have grown to over 400 employees across 12 countries and have been granted the status of fully regulated MVNO in 9 of them.
As innovators in eSIM-based GSM mobile services, 1GLOBAL caters to both businesses and individuals with products including mobile call and SMS recording services for businesses, remote SIM provisioning, IOT solutions, Telco-as-a-Service for travel companies, and affordable roaming for everyday consumers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122511628/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom